Biocon Biologics and Voluntis collaborate on digital therapeutics for insulins
Insulia is the first digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon Biologics
Biocon Biologics gets DCGI approval for emergency use of CytoSorb to treat critical COVID-19…
US FDA recently approved CytoSorb for emergency use in COVID-19 patients
EU GMP Certification for Biocon Biologics Drug Substance Facilities in Bengaluru
These facilities were inspected by the regulatory agency between January 20 and 23, 2020
Biocon and Mylan Launch Fulphila, Biosimilar Pegfilgrastim, in Australia
The approval of Fulphila was based on a comprehensive package of analytical, nonclinical and clinical data, which confirmed that…
Biocon gets three observations from US health regulator for Malaysia facility
The FDA has set a target action date for its insulin glargine application in June 2020
Biocon sees revenue growth of 14 per cent to Rs 1,784 crores in Q3FY20
EBITDA at Rs 480 crores, up 18 per cent
True North to invest Rs 536.25 cr in Biocon Biologics for 2.44 per cent stake
Post the completion of this transaction, Biocon will hold 96.07 per cent stake in Biocon Biologics
Biocon appoints Siddharth Mittal as its CEO and Joint MD
He takes over from Dr Arun Chandavarkar who retired as Chief Executive Officer & Joint Managing Director of Biocon on November…
USFDA approves Biocon’s sBLA for Pegfilgrastim new manufacturing facility
Expanded capacity will enable greater patient access globally
Biocon features in the ASIA IP ELITE list for the fourth consecutive year
Biocon Biologics debuts on the ASIA IP ELITE 2019 list